Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Medicine, Internal medicine, Chemotherapy, Minimal residual disease, Imatinib, and Dasatinib.
Epigenomic diagnosis and prognosis of Acute Myeloid Leukemia
Improving Health Care Transition for Young Patients With Sickle Cell Disease Through Quality Network
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial
PDCT-08. TRACKING THE T CELL REPERTOIRE AFTER ADOPTIVE CELL THERAPY IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA
CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
PDCT-15. Re-MATCH: A PHASE 2 MULTI-INSTITUTIONAL CLINICAL TRIAL OF ADOPTIVE CELLULAR THERAPY FOLLOWING MYELOABLATIVE OR NON-MYELOABLATIVE CHEMOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH RECURRENT MEDULLOBLASTOMA AND PNETs
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031
Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children’s Oncology Group Study AALL0031